Drug intelligence / Profile preview

Brozopentyl Sodium

Development stage: Unknown
Lead developer: Ausun Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

Brozopentyl Sodium (BZP) is a novel pharmaceutical agent under development for the treatment of ischemic stroke. Preclinical pharmacological studies have shown promising results, leading to its first-in-human investigation. The drug is administered via intravenous infusion and has demonstrated a good safety profile, tolerability, and predictable pharmacokinetic characteristics in healthy volunteers. It has a bioactive metabolite, BNBP.

Other names: 布罗佐喷钠brozopentyl sodium注射用布罗佐喷钠

Targets

IL1B (Interleukin-1 beta)PLA2G4A (Cytosolic phospholipase A2 alpha)TNFA (Tumor necrosis factor alpha (soluble))15-LOX (Lysyl Oxidase)Kir (Inward-rectifier potassium channels)MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on Brozopentyl Sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brozopentyl Sodium.

Explore the full profile